C
GYRE icon

Covestor’s Gyre Therapeutics GYRE Stock Holding History

Covestor’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
14
+8
+133% +$62 ﹤0.01% 2466
2025
Q4 		$0 Hold
6
– – ﹤0.01% 2445
2025
Q3 		$0 Hold
6
– – ﹤0.01% 2468
2025
Q2 		$0 Sell
6
-1
-14% -$9 ﹤0.01% 2421
2025
Q1 		$0 Hold
7
– – ﹤0.01% 2426
2024
Q4 		$0 Buy
7
+1
+17% +$13 ﹤0.01% 2436
2024
Q3 		$0 Buy
+6
New +$77 ﹤0.01% 2420

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Covestor's GYRE Position: Q1 2026 in Review

Covestor increased its Gyre Therapeutics (GYRE) stake by 133% in Q1 2026, buying an estimated $62 and bringing the position to 14 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2466.

Covestor first reported a position in GYRE in Q3 2024 and has held it in 7 quarters since. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Covestor held 14 shares of Gyre Therapeutics worth $0 as of Q1 2026.
  • Covestor bought 8 Gyre Therapeutics shares in Q1 2026, an estimated $62.
  • Gyre Therapeutics made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2466 holding.
  • Covestor first reported a position in Gyre Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.